Any current/future new fundraising through debt or equity?

The company currently has cash of INR 1,826 million and has reduced finance costs after IPO, improving capital efficiency. Future expansions, including adding roughly 450 beds at Greater Noida and Noida Extension in 2-2.5 years, are expected to be funded largely through internal accruals. There is scope for taking on additional debt if required, though efforts are made to utilize internal accruals and existing cash. The company is also exploring acquisition opportunities, including operational and management (O&M) models, which require less capital outlay. Overall, the financing strategy for g

Any current/future capex/capital investment/strategic investment?

Brownfield expansions at Noida Extension and Greater Noida hospitals: adding 250 beds at Noida Extension and 200 beds at Greater Noida, expected in 2-2.5 years, with capex around INR 65 lakh per bed funded through internal accruals. Capex increased by INR 60 crores this quarter primarily due to medical equipment including robotics and advanced surgical tools for neurosurgery and cardiac surgeries. Strategic investments in robotics and super-specialty services, including oncology and organ transplant programs. Plans for further bed capacity expansion aiming to reach 2,800 to 3,000 beds by FY '2

Future growth expectations in sales/revenue/volumes?

Expect revenue close to INR 1000 crores this year, driven by growth across facilities (Page 17). Inpatient volume grew 28% YoY to 15,235 this quarter, with notable growth in Noida Extension (81% revenue increase, 38% contribution) (Pages 5, 9). ARPOB (Average Revenue Per Occupied Bed) is improving, reaching INR 30,551 in Q1; expected to increase further with improved case mix and pricing (Pages 5, 17). Capacity expansion underway: 200 beds in Greater Noida and 250 beds in Noida Extension planned within 2-2.5 years, expected to achieve over 50% utilization within two years post-expansion

Future growth expectations in earnings/operating earnings/profits/EPS?

Noida Hospital has peaked with little growth expected; any growth driven by clinical mix changes resulting in single-digit increases in ARPOB. EBITDA margins across existing facilities (excluding the loss-making Faridabad hospital) expected to be stable or improve, maintaining above 26-26.5%. Faridabad hospital anticipated to reach above 20% EBITDA margins within 3 years, aided by increasing ARPOB and robotic surgeries. Overall consolidated margins expected to sustain around 25%, with minor fluctuations due to new acquisitions and expansions. ARPOB is on an improving trajectory, crossi

Current/ Expected Orderbook/ Pending Orders?

The company has a strong pipeline for future expansions, including targeting a bed capacity of 2,800 to 3,000 beds by FY '28, nearly doubling current capacity. Expansion plans focus on North India markets: Delhi-NCR, Uttar Pradesh, Punjab, and Bihar. Land parcels adjacent to Noida Extension and Greater Noida hospitals will see capacity additions of 250 beds and 200 beds respectively, expected to be ready in about 2.5 years. Discussions are ongoing for acquiring or operating a 400-bed hospital under an O&M (Operations & Management) model, which requires lower capital expenditure. The company pl

Yatharth Hospit.Q1 FY25Healthcare Services

Yatharth Hospit. Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,034P/E: 59.6Market Cap: ₹10.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Expect revenue close to INR 1000 crores this year, driven by growth across facilities (Page 17).
Inpatient volume grew 28% YoY to 15,235 this quarter, with notable growth in Noida Extension (81% revenue increase, 38% contribution) (Pages 5, 9).
ARPOB (Average Revenue Per Occupied Bed) is improving, reaching INR 30,551 in Q1; expected to increase further with improved case mix and pricing (Pages 5, 17).
Capacity expansion underway: 200 beds in Greater Noida and 250 beds in Noida Extension planned within 2-2.5 years, expected to achieve over 50% utilization within two years post-expansion (Pages 11, 17).
Addition of 3,000 beds targeted by FY 2028 via brownfield expansions, acquisitions, and O&M models, primarily in North India, Delhi NCR, UP, and Rajasthan (Pages 7, 11-12).
Faridabad hospital occupancy to grow from current 10% to 30% by year-end, contributing to revenues (Page 10).
Oncology and super-specialty services expected to increase contribution and ARPOB, supporting volume growth (Pages 5, 9).

Margin guidance

Category 3

Noida Hospital has peaked with little growth expected; any growth driven by clinical mix changes resulting in single-digit increases in ARPOB.
EBITDA margins across existing facilities (excluding the loss-making Faridabad hospital) expected to be stable or improve, maintaining above 26-26.5%.
Faridabad hospital anticipated to reach above 20% EBITDA margins within 3 years, aided by increasing ARPOB and robotic surgeries.
Overall consolidated margins expected to sustain around 25%, with minor fluctuations due to new acquisitions and expansions.
ARPOB is on an improving trajectory, crossing INR 30,000 mark recently; Jhansi-Orchha ARPOB expected to rise to INR 15,000-18,000.
Expansion plans to add 450 beds at Noida Extension and Greater Noida within 2-2.5 years, driving future revenue growth.
Oncology segment growing well, contributing 10% overall and projected to increase further.
EBITDA expected to improve as new capacities ramp up and operational efficiencies are realized.

See what Yatharth Hospit. management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

The company currently has cash of INR 1,826 million and has reduced finance costs after IPO, improving capital efficiency.
Future expansions, including adding roughly 450 beds at Greater Noida and Noida Extension in 2-2.5 years, are expected to be funded largely through internal accruals.
There is scope for taking on additional debt if required, though efforts are made to utilize internal accruals and existing cash.
The company is also exploring acquisition opportunities, including operational and management (O&M) models, which require less capital outlay.
Overall, the financing strategy for growth includes a mix of internal accruals, available cash, and selective debt, with no specific mention of planned equity fundraising in the near term.

Order book

The company has a strong pipeline for future expansions, including targeting a bed capacity of 2,800 to 3,000 beds by FY '28, nearly doubling current capacity.
Expansion plans focus on North India markets: Delhi-NCR, Uttar Pradesh, Punjab, and Bihar.
Land parcels adjacent to Noida Extension and Greater Noida hospitals will see capacity additions of 250 beds and 200 beds respectively, expected to be ready in about 2.5 years.
Discussions are ongoing for acquiring or operating a 400-bed hospital under an O&M (Operations & Management) model, which requires lower capital expenditure.
The company plans at least one acquisition each year in the next few years in the target regions.
Funding for these expansions will come from a mix of internal accruals, cash on books, and debt if required.
Current consistent progress on various expansions and acquisitions indicates a solid orderbook pipeline.

See what Yatharth Hospit. management said on order book — free account, 30 seconds.

Capex plans

Yes

Brownfield expansions at Noida Extension and Greater Noida hospitals: adding 250 beds at Noida Extension and 200 beds at Greater Noida, expected in 2-2.5 years, with capex around INR 65 lakh per bed funded through internal accruals.
Capex increased by INR 60 crores this quarter primarily due to medical equipment including robotics and advanced surgical tools for neurosurgery and cardiac surgeries.
Strategic investments in robotics and super-specialty services, including oncology and organ transplant programs.
Plans for further bed capacity expansion aiming to reach 2,800 to 3,000 beds by FY '28 through a mix of internal accruals, debt, and O&M model acquisitions to limit asset-heavy outflows.
Ongoing efforts to acquire new hospitals, with recent acquisitions in Jhansi-Orchha and Faridabad, and active discussions for two more hospitals in Delhi NCR and Uttar Pradesh.
Signing NDA with major audit firms for process strengthening, indicating strategic governance investments.

Track Yatharth Hospit. — get its next earnings analysis in your feed

How does Yatharth Hospit. rank vs peers in Healthcare Services?

Pro feature

ThisYatharth Hospit.

Rev 2Mar 3

See where Yatharth Hospit. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Yatharth Hospit. rank in Healthcare Services?

Compare Yatharth Hospit. against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Yatharth Hospit.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →